This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
View Post 6 min This content is machine translated Type 2 diabetes: current trends Dual GIP/GLP-1 receptor agonist as an innovative therapeutic option The goals of individualized diabetes treatment today are not limited to achieving glycemic control, but many blood glucose-lowering drugs have clinically relevant additional benefits. Incretin-based therapies are particularly interesting for…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…
View Post 4 min This content is machine translated Type 2 diabetes “Swiss Diabetes Guide” – digital tool supports physicians in drug selection The treatment options for type 2 diabetes mellitus are very complex. In addition to the large number of new active ingredients on the market, the scientific data base is constantly…
View Post 2 min This content is machine translated Glucagon-like peptide 1 (GLP1) analogues The future of diabetes management has begun Diabetes does not hurt – one would almost like to add “unfortunately”. This is because the number of unreported cases of affected patients is still high. Possible late effects of…
View Post 4 min This content is machine translated GLP-1 receptor agonists (GLP-1-RA) Type 2 diabetics benefit from dulaglutide in several ways The ADA/EASD guidelines recommend individualized therapy choices for type 2 diabetics. GLP-1 receptor agonists not only improve glycemic control, but also support weight loss, reduce the risk of cardiovascular disease,…
View Post 4 min This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of…
View Post 4 min This content is machine translated Diabetes mellitus type 2 New Swiss guidelines support cardiovascular disease control The treatment of type 2 diabetes mellitus has undergone a transformation in recent years with the approval of new drug classes. The focus is no longer on pure glycemic control,…
